All In Biotech

Drug Trial Radar · NCT07488949

Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF)

Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF): A Prospective Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Apr 9, 2024

Primary completion

Dec 31, 2030

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Fang WangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Prospective Randomized Controlled Trial, the goal of this clinical trial is to evaluate the efficacy and safety of doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE), and to assess subsequent reproductive outcomes. Participants will be randomly assigned to one of two groups and will receive the assigned treatment. Participants will be followed for reproductive outcomes, including pregnancy , ongoing pregnancy, spontaneous miscarriage, and live birth.

Conditions

  • Chronic Endometritis

Interventions

  • Doxycycline combined with MedroxyprogesteroneDrug

    doxycycline 200 mg/day (100 mg twice daily) combined with medroxyprogesterone acetate(MPA) 24 mg/day (8 mg three times daily) for 14 days

  • Doxycycline combined with placeboDrug

    doxycycline 200 mg/day (100 mg twice daily) with placebo 24 mg/day (8 mg three times daily) for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure rate of chronic endometritisTime frame: At 8 weeks after completion of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.